PPARG and non-small cell lung carcinoma: In addition to PTEN, PPARγ agonist rosiglitazone also downregulates Akt/mTOR/p70S6K signal cascade, which inhibits NSCLC cell proliferation through PPARγ-dependent and PPARγ-independent signaling [48].